CA2498938A1 - Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin - Google Patents
Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin Download PDFInfo
- Publication number
- CA2498938A1 CA2498938A1 CA002498938A CA2498938A CA2498938A1 CA 2498938 A1 CA2498938 A1 CA 2498938A1 CA 002498938 A CA002498938 A CA 002498938A CA 2498938 A CA2498938 A CA 2498938A CA 2498938 A1 CA2498938 A1 CA 2498938A1
- Authority
- CA
- Canada
- Prior art keywords
- substance
- component
- aggregates
- amphipatic
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41784702P | 2002-10-11 | 2002-10-11 | |
| US60/417,847 | 2002-10-11 | ||
| US10/357,617 | 2003-02-04 | ||
| US10/357,618 | 2003-02-04 | ||
| US10/357,618 US20040105881A1 (en) | 2002-10-11 | 2003-02-04 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| US10/357,617 US7473432B2 (en) | 2002-10-11 | 2003-02-04 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| PCT/EP2003/011202 WO2004032900A1 (en) | 2002-10-11 | 2003-10-09 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2498938A1 true CA2498938A1 (en) | 2004-04-22 |
Family
ID=32995875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002498938A Abandoned CA2498938A1 (en) | 2002-10-11 | 2003-10-09 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
Country Status (21)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US11724985B2 (en) | 2020-05-19 | 2023-08-15 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69901284T2 (de) | 1999-01-27 | 2002-11-28 | Idea Ag | Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern |
| SI1031346T1 (en) | 1999-01-27 | 2002-08-31 | Idea Ag | Noninvasive vaccination through the skin |
| WO2001001962A1 (en) | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US20040105881A1 (en) | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| JP2008519784A (ja) * | 2004-11-12 | 2008-06-12 | イデア アクチェンゲゼルシャフト | 皮膚状態の治療における拡張表面凝集体 |
| RU2491096C9 (ru) * | 2007-09-13 | 2014-02-10 | Басф Се | Применение гидрофобин-полипептидов в качестве усилителя пенетрации |
| PL214538B1 (pl) | 2009-05-28 | 2013-08-30 | P P F Hasco Lek Spolka Akcyjna | Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen |
| AU2010255391C1 (en) * | 2009-06-03 | 2016-10-27 | Sequessome Technology Holdings Limited | Formulations for the treatment of deep tissue pain |
| PH12012500360A1 (en) * | 2009-08-21 | 2019-07-10 | Targeted Delivery Tech Limited | Vesicular formulations |
| WO2012126966A2 (en) * | 2011-03-21 | 2012-09-27 | Gregor Cevc | Optimised preparations of highly adaptable aggregates |
| US20140017301A1 (en) * | 2011-03-21 | 2014-01-16 | Gregor Cevc | Drug-free compositions and methods for diminishing peripheral inflammation and pain |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| CA2889664C (en) * | 2012-10-26 | 2020-12-29 | Oxford Nanopore Technologies Limited | Droplet interfaces |
| RU2524649C1 (ru) * | 2013-07-24 | 2014-07-27 | Станислав Анатольевич Кедик | Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма |
| KR102325654B1 (ko) * | 2013-07-31 | 2021-11-12 | 시퀘솜 네크놀로지 홀딩스 리미티드 | 소포체 |
| WO2015048554A1 (en) * | 2013-09-26 | 2015-04-02 | National University Of Singapore | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
| CN105658782B (zh) * | 2013-10-25 | 2018-08-07 | 凸版印刷株式会社 | 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法 |
| EP3316856B1 (en) | 2015-06-30 | 2021-04-07 | Sequessome Technology Holdings Limited | Blended formulations |
| US12364661B2 (en) | 2015-11-20 | 2025-07-22 | The Regents Of The University Of California | Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| US20200030457A1 (en) * | 2017-04-03 | 2020-01-30 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| KR102149190B1 (ko) | 2018-04-09 | 2020-08-28 | 경상대학교산학협력단 | 액중 방전 마이크로젯 약물 전달장치 |
| KR102209397B1 (ko) | 2020-07-21 | 2021-01-29 | 경상대학교산학협력단 | 액중 방전 마이크로젯 약물 전달장치 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992003122A1 (de) * | 1990-08-24 | 1992-03-05 | Gregor Cevc | Präparat zur wirkstoffapplikation in kleinsttröpfchenform |
| DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
| US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| DE4447287C1 (de) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| HUP0104424A3 (en) * | 1998-12-23 | 2002-12-28 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
| DE69901284T2 (de) * | 1999-01-27 | 2002-11-28 | Idea Ag | Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern |
-
2003
- 2003-10-09 HR HR20050421A patent/HRPK20050421B3/xx not_active IP Right Cessation
- 2003-10-09 DE DE60318227T patent/DE60318227T2/de not_active Expired - Lifetime
- 2003-10-09 PL PL377202A patent/PL377202A1/pl not_active Application Discontinuation
- 2003-10-09 EP EP03757944A patent/EP1551370B1/en not_active Expired - Lifetime
- 2003-10-09 AT AT03757944T patent/ATE381316T1/de active
- 2003-10-09 KR KR1020057004979A patent/KR20050055723A/ko not_active Ceased
- 2003-10-09 EA EA200500632A patent/EA010407B1/ru not_active IP Right Cessation
- 2003-10-09 EP EP06023467A patent/EP1829528A3/en not_active Withdrawn
- 2003-10-09 MX MXPA05003744A patent/MXPA05003744A/es active IP Right Grant
- 2003-10-09 CN CN2003801013013A patent/CN1703199B/zh not_active Expired - Fee Related
- 2003-10-09 EP EP06023468A patent/EP1815847A3/en not_active Withdrawn
- 2003-10-09 CA CA002498938A patent/CA2498938A1/en not_active Abandoned
- 2003-10-09 ES ES03757944T patent/ES2298566T3/es not_active Expired - Lifetime
- 2003-10-09 EP EP06023466A patent/EP1829527A3/en not_active Withdrawn
- 2003-10-09 DK DK03757944T patent/DK1551370T3/da active
- 2003-10-09 SI SI200331142T patent/SI1551370T1/sl unknown
- 2003-10-09 PT PT03757944T patent/PT1551370E/pt unknown
- 2003-10-09 WO PCT/EP2003/011202 patent/WO2004032900A1/en active Application Filing
- 2003-10-09 NZ NZ538571A patent/NZ538571A/en not_active IP Right Cessation
- 2003-10-09 AU AU2003273977A patent/AU2003273977B2/en not_active Ceased
- 2003-10-09 JP JP2005500984A patent/JP2006505619A/ja active Pending
- 2003-10-09 BR BR0315148-4A patent/BR0315148A/pt not_active IP Right Cessation
- 2003-10-09 EP EP06023465A patent/EP1815846A3/en not_active Withdrawn
-
2005
- 2005-02-15 JP JP2005037992A patent/JP4555111B2/ja not_active Expired - Fee Related
- 2005-03-30 IS IS7776A patent/IS7776A/is unknown
- 2005-05-10 NO NO20052281A patent/NO20052281L/no not_active Application Discontinuation
-
2008
- 2008-11-04 JP JP2008283199A patent/JP2009108070A/ja active Pending
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US12312375B2 (en) | 2017-10-09 | 2025-05-27 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11939346B2 (en) | 2017-10-09 | 2024-03-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US11834410B2 (en) | 2020-05-19 | 2023-12-05 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11746088B2 (en) | 2020-05-19 | 2023-09-05 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11724985B2 (en) | 2020-05-19 | 2023-08-15 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11958807B2 (en) | 2020-05-19 | 2024-04-16 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12110272B2 (en) | 2020-05-19 | 2024-10-08 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12291499B2 (en) | 2020-05-19 | 2025-05-06 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200405480B (en) | Aggregate with increased deformability comprising at least three amphipats for improved transport through semi permeable barriers and for the non invasive drug application in vivo especially through the skin | |
| AU2003273977B2 (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| ES2325364T3 (es) | Analgesicos. | |
| US20080095722A1 (en) | Extended Surface Aggregates in the Treatment of Skin Conditions | |
| HK1110505A (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| HK1110504A (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| HK1104967A (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| HK1104966A (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| EP4463139A2 (en) | Ultraflexible liposomes in gel formulation | |
| HK1079113B (en) | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | |
| HK1149499A (en) | Aggregate with increased deformability, comprising at least three amphipats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |